Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07786766 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT07786766 · ClinicalTrials.gov record · last posted 2026-08-26

Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2 Fusion/Rearrangement-Positive Cholangiocarcinoma

Name: Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2 Fusion/Rearrangement-Positive Cholangiocarcinoma — clinical trial record (NCT07786766)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorHaitao Zhao, MD

Started2026-08-20

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This is a prospective, single-arm, phase II clinical study. Patients with advanced cholangiocarcinoma harboring FGFR2 fusions or rearrangements who have either not previously received standard therapy or have experienced treatment failure following standard therapy will be screened for eligibility and enrolled in the study after providing written informed consent.

Trial Details

NCT Number	NCT07786766
Lead Sponsor	Haitao Zhao, MD
Conditions	Biliary Tract Cancer (BTC)
Enrollment	154 participants
Start Date	2026-08-20
Primary Completion	2027-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-26